Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...
Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...
Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...
Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...
Hosted on MSN7d
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy RecommendationFintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's ...
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback